Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

NCT02639182

Metastatic Renal Cell Carcinoma

COMPLETED PHASE2

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

NCT00282048

Kidney Neoplasms Carcinoma, Renal Cell

COMPLETED PHASE2

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

NCT00678392

Kidney Neoplasms

COMPLETED PHASE3

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

NCT00920816

Kidney Neoplasms

COMPLETED PHASE3

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

NCT01255137

Adrenal Cortex Neoplasms

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\]. Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\].

5-year survival information to be updated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Renal Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-Interventional Study

Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\].

axitinib: observational study

Intervention Type DRUG

Non-interventional observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

axitinib: observational study

Non-interventional observational study

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AG-013736

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\] and may have also participated in study A4061008 \[NCT00828919\]